HARMONY BIOSCIENCES HOLDINGS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $91.00K, a 73.78% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.33M, a 131.94% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $347.00K, a 41.63% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $573.00K, a 14.99% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $8.43M, a 10.01% decline from fiscal 2021.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $9.37M, a 3034.11% increase from fiscal 2020.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $299.00K, a 251.76% increase from fiscal 2019.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, stock options exercised for fiscal 2019 was $85.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-09-30 | $91.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.33M 10-Q · filed 2025-08-05 | |
| 2024-09-30 | $347.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $573.00K 10-Q · filed 2025-08-05 | |
| 2023-09-30 | $245.00K 10-Q · filed 2024-10-29 | $7.47M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $674.00K 10-Q · filed 2024-08-06 | $9.37M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $3.40M 10-Q · filed 2024-04-30 | $9.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $8.43M 10-K · filed 2025-02-25 |
| 2022-09-30 | $2.14M 10-Q · filed 2023-10-31 | $12.85M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.25M 10-Q · filed 2023-08-01 | $11.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.88M 10-Q · filed 2023-05-02 | $11.24M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $9.37M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.13M 10-Q · filed 2022-11-01 | $1.81M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $648.00K 10-Q · filed 2022-08-02 | $709.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $12.00K 10-Q · filed 2022-05-03 | $161.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $299.00K 10-K · filed 2023-02-21 |
| 2020-09-30 | $33.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-10 | |
| 2020-03-31 | $151.00K 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $85.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |